NTLA
Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.58
+1.40%Year over year
Reported trailing growth
- Revenue
- +12.6%
- EBITDA
- +19.8%
- EBIT
- +17.3%
- EPS
- +28.4%
- Free cash flow
- +17.3%
- Operating cash flow
- +17.2%
Forward estimates
Based on analyst estimates
- Revenue
- +11.7%
- EBITDA
- +0.4%
- EPS
- +10.9%
Three-year CAGR
- Revenue
- +9.1%
- EBITDA
- +22.0%
- EBIT
- +17.5%
- Net income
- +20.5%
- EPS
- +27.4%
- Free cash flow
- +0.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026